<DOC>
	<DOCNO>NCT01801644</DOCNO>
	<brief_summary>To evaluate efficacy safety neoadjuvant gemcitabine cisplatin ( gem/cis ) locally advanced bladder cancer .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Locally Advanced Bladder Cancer</brief_title>
	<detailed_description>Patients locally advance transitional cell bladder cancer receive 3 cycle neoadjuvant gemcitabine/cisplatin radical cystectomy . Patients histologically confirm clinical stage T2-T4a , N0-2 bladder cancer go include . After CT scan thorax abdomen plus MRI pelvis patient receive chemotherapy . Pathologic response rate assess surgery institutional pathologic review . Safety go assess accord National Cancer Institute Common Toxicity Criteria ( CTC , version 3.0 ) .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>18 year age histologically confirm stage T2 , T3 T4a urothelial bladder cancer N0N2 Eastern Cooperative Oncology Group ( ECOG ) performance status 01 bone marrow reserve ( neutrophil count &gt; 1500 cell per μL , platelet count &gt; 100 000 per μL ) count hepatic function ( serum bilirubin &lt; 2,5 time upper limit normal , serum aminotransferase ≤2,5 time upper limit normal ) . renal function creatinine clearance &gt; 60ml/min metastatic disease serious uncontrolled concurrent medical illness pregnancy history malignancy ( exception excise cervical basal skin squamouscell carcinoma ) nontransitional cell bladder cancer creatinine clearance &lt; 60ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>gem/cis</keyword>
</DOC>